

Index

A

- ABT-510, 256–257
- Adherens junction, 306–310
- Aflibercept, 470
- Age-related macular degeneration (AMD), *see also*
 - Ocular neovascularization
 - angiogenesis inhibition therapy, 359–362
 - HTRA1 polymorphisms, 425
 - vascular normalization studies, 346
- Akt, vascular endothelial growth factor receptor signaling, 179, 183–184, 309
- ALK1, 455
- AMD, *see* Age-related macular degeneration
- Angiopoietin–Tie signaling
 - angiopoietin-1 knockout effects, 237
 - angiopoietin-2
 - distribution, 237
 - enzyme-linked immunosorbent assay, 240
 - knockout effects, 238, 241
 - pathology
 - inflammation-induced vascular remodeling, 241–242
 - overview, 239–241
 - tumor angiogenesis and growth, 242–244
 - prospects for study, 244
 - cellular and vascular effects, 238–239
 - placenta, 383
 - Tie
 - isoforms and signaling, 236–237
 - receptor tyrosine phosphatase, 238
 - vascular normalization targeting, 340–341
- Angiostatin, 324
- Antithrombin III, 3–4
- Apoptosis
 - CD36 induction, 252–253
 - VEGFR-2 modulation, 183–184
- Arteriogenesis, pathogenesis, 81
- Arteriovenous malformation (AVM), *see also* Hereditary
 - hemorrhagic telangiectasia
 - capillary malformation–arteriovenous malformation, 437–439, 452–453
 - cerebral cavernous malformation, 439–440, 453–454
 - cutaneomucosal venous malformation, 440–441
 - genetic syndromes, 438
 - glomulovenous malformation, 451–452
 - overview, 435–436

- Atherosclerosis
 - placental growth factor blockade therapy, 221
 - vascular normalization studies, 347–348
- AVM, *see* Arteriovenous malformation
- Axitinib, 470
- Axon
 - outgrowth and neuronal migration guidance
 - by blood vessels, 164–165
 - vascular endothelial growth factor guidance cue for growing axons, 168–169

B

- B16F10, 255
 - Basic fibroblast growth factor, *see* Fibroblast growth factor-2
 - Bevacizumab
 - age-related macular degeneration management, 362
 - choroidal neovascular membrane studies, 362
 - clinical trials
 - breast cancer, 474–475, 478
 - colorectal cancer, 471–474, 477
 - glioblastoma, 476, 482
 - non-small-cell lung cancer, 475, 479
 - renal cell carcinoma, 476, 480–482
 - diabetic macular edema management, 368
 - history of development, 468, 470
 - neovascular glaucoma management, 365–367
 - proliferative diabetic retinopathy management, 365
 - retinal vein occlusion management, 371
 - toxicity, 483–485
 - Biomarkers, antiangiogenesis therapy, 485–487
 - Blood pressure, lymphatic regulation, 104
 - Blood vessel
 - invertebrates
 - formation, 77
 - morphology, 77–78
 - overview, 75–77
 - vertebrate formation, 78–81
 - Bone fracture, placental growth factor repair role, 220
 - Breast cancer, antiangiogenesis therapy, 474–475, 478–479
 - Brivanib alamine, 470
- ## C
- CAF, *see* Carcinoma-associated fibroblast
 - Candidate gene, angiogenesis response studies in humans, 416–417

Index

- Canstatin, 324
Capillary malformation–arteriovenous malformation (CM-AVM), 437–439, 452–453
Carcinoma-associated fibroblast (CAF), 397–400
CCBE1, 125
CCM, *see* Cerebral cavernous malformation
CD34, endothelial progenitor cell marker, 19–22
CD36
 apoptosis induction, 252–255
 interactions with VEGFR2, 251–252
 nitric oxide signaling suppression via thrombospondin, 253–255
CD45, endothelial progenitor cell marker, 21
CD47, nitric oxide signaling suppression via thrombospondin, 253–255
CD133, endothelial progenitor cell marker, 20–22
Cediranib, 470, 482
Cerebral cavernous malformation (CCM)
 endothelial cell junction defects, 313–314
 gene mutations, 453–454
 overview, 439–440
c-fms, 101
Choroidal neovascular membranes, *see* Ocular neovascularization
Cilengitide, 326–327
Cirrhosis, placental growth factor blockade therapy, 221
CLEC-2, lymphangiogenesis role, 122
CM-AVM, *see* Capillary malformation–arteriovenous malformation
Colitis, placental growth factor levels, 220
Colorectal cancer, antiangiogenesis therapy, 471–474, 477
Connective tissue growth factor (CTGF), 90
Corticosteroids, *see* Infantile hemangioma
COUP-TFII
 artery–vein specification in zebrafish, 142
 lymphangiogenesis role, 119–120, 122
CTGF, *see* Connective tissue growth factor
Cutaneous mucosal venous malformation (VMCM), 440–441, 450
- D**
- DC, *see* Dendritic cell
Delayed-type hypersensitivity, placental growth factor blockade therapy, 221
Delta-like ligand-1 (Dll1), 45–46, 49–51, 124
Delta-like ligand-4 (Dll4), 68
Dendritic cell (DC)
 corneal inflammation, 106–107
 lymphatic endothelial cell interactions, 102
Diabetes
 endothelial progenitor cell defects, 24
 lymphangiogenesis and wound healing, 102–103
 macular edema, *see* Ocular neovascularization
 retinopathy, *see* Ocular neovascularization
Dicer, role in endothelial cell function and angiogenesis, 86–87
Dll1, *see* Delta-like ligand-1
Dll4, *see* Delta-like ligand-4
- E**
- EC, *see* Endothelial cell
ECFC, *see* Endothelial colony-forming cell
ECM, *see* Extracellular matrix
Emphysema, placental growth factor blockade therapy, 222
EMT, *see* Epithelial–mesenchymal transition
Endoglin, 387, 437, 455
Endosome, vascular endothelial growth factor receptor internalization and signaling, 187
Endostatin, 324
Endothelial cell (EC), *see also* Stalk cell; Tip cell
 Dicer role in cell function and angiogenesis, 86–87
 heterogeneity mechanisms, 4–6, 47–41
 junctions between cells
 adherens junction, 306–310
 cerebral cavernous malformation defects, 313–314
 complexes between adhesion molecules and growth factor receptors, 310–311
 embryonic development studies, 311–313
 mutation studies in mouse and zebrafish, 308–309, 311–313
 organ and vascular side/district specificity, 310
 prospects for study, 315
 structure and signaling activity, 305–307
 tight junction, 306–310
 tumor defects, 314–315
 Kaposi's sarcoma herpes virus and lymphatic reprogramming of vascular endothelial cells, 127
 leukocyte-mediated remodeling and lymphatic endothelium expansion, 100–104
 lymphatic endothelial cell, *see* Lymphangiogenesis
 lymphatic versus blood vessel cells, 114–116
 microRNA synthesis regulation, 91–93
 phenotypes, 2–4, 41–43
 therapeutic targeting, 10–11
 thrombospondin inhibition of migration and proliferation, 253
 tubulogenesis
 cell–cell junctions, 78
 polarity, 65–66, 78–79
 tumor, *see* Tumor endothelial cell
 vascular endothelial growth factor response in developing vessels, 30–33
Endothelial colony-forming cell (ECFC), 23–25, 287
Endothelial progenitor cell (EPC)
 blood vessel formation, repair, and modeling, 16–18
 definition, 24–25

identification and markers, 18–24, 106
overview, 15–16
pathology, 24
vessel wall cells, 287
zebrafish origin and specification, 138–140
Endothelial-specific adhesion molecule (ESAM), 123
EPC, *see* Endothelial progenitor cell
Ephrin B2, artery–vein specification in zebrafish,
141–142
Epithelial–mesenchymal transition (EMT), 106
EPO, *see* Erythropoietin
ERK, *see* Extracellular signal-regulated kinase
Erythropoietin (EPO), ocular neovascularization role,
359, 363
ESAM, *see* Endothelial-specific adhesion molecule
Estrogen, 299, 403
ETS factors, endothelial precursor cell origin and
specification in zebrafish, 138–140
Extracellular matrix (ECM)
 integrin modulation of vascular endothelial growth
 factor receptor signaling, 186–187
 tubulogenesis modulation, 66–67
Extracellular signal-regulated kinase (ERK), vascular
 endothelial growth factor receptor
 signaling, 178–179, 181
Eye, *see* Ocular neovascularization

F

FAK, *see* Focal adhesion kinase
FGF-2, *see* Fibroblast growth factor-2
Fibrin, 207–208
Fibroblast growth factor-2 (FGF-2), stromal
 angiogenesis regulation in tumor
 microenvironment, 400–401
Flk-1, *see* VEGFR-2
Flow cytometry, endothelial progenitor cell
 identification with polychromatic
 technique, 21–22
Flt-1, *see* VEGFR-1
Focal adhesion kinase (FAK), 186
FOXC2, lymphangiogenesis role, 120
Fyn, apoptosis induction, 252–253

G

Galectin-3, polymorphisms, 424
Gastric cancer, antiangiogenesis therapy, 483
Genome-wide association studies, angiogenesis
 response genes, 424–425
GJC2, 125, 457
Glioblastoma, antiangiogenesis therapy, 476, 481–482
Glomeruloid microvascular proliferation (GMP), 206
Glomulin, 451
Glomulovenous malformation (GVM), gene mutations,
 451–452

GLUT-1, 298
GMP, *see* Glomeruloid microvascular proliferation
GPR124, 164
GVM, *see* Glomulovenous malformation

H

Hemangioma, *see* Infantile hemangioma
Hematopoietic stem cell (HSC), vasculogenic potential
 inhibition by corticosteroids, 298
Hepatocellular carcinoma, antiangiogenesis therapy,
 482–483
Hepatocyte growth factor (HGF), 450
HER-2, 342
Hereditary hemorrhagic telangiectasia (HHT)
 animal models, 437
 clinical features, 436
 gene mutations, 436–437, 454–456
 vascular normalization studies, 347
HEV, *see* High endothelial venule
HGF, *see* Hepatocyte growth factor
HGS, 91
HHT, *see* Hereditary hemorrhagic telangiectasia
HIF-1 α , *see* Hypoxia-inducible factor-1 α
High endothelial venule (HEV), 3
HLTS, *see* Hypotrichosis–lymphedema–telangiectasia
 syndrome
HSC, *see* Hematopoietic stem cell
HTRA1, 425
Hypotrichosis–lymphedema–telangiectasia syndrome
 (HLTS), gene mutations, 458–459
Hypoxia-inducible factor-1 α (HIF-1 α), 43, 91, 398,
 421–422, 497

I

IGF-II, *see* Insulin-like growth factor-II
IH, *see* Infantile hemangioma
IL-8, *see* Interleukin-8
Infantile hemangioma (IH)
 corticosteroid therapy
 mechanisms of action
 estrogen antagonism, 299
 hematopoietic stem cell vasculogenic
 potential inhibition, 298
 nuclear factor- κ B suppression, 299
 proangiogenic profile modification, 298–299
 VEGF-A downregulation, 298
 overview, 297–298
 epidemiology, 295
 gene mutations, 445, 448
 phases, 295–297
 propranolol therapy
 mechanisms of action
 cell differentiation effects, 301
 hemodynamic effects, 300

Index

- Infantile hemangioma (IH) (*Continued*)
 proangiogenic cytokine downregulation,
 300–301
 VEGF-A downregulation, 300
 overview, 299–300
- Inflammation-induced vascular remodeling,
 angiopoietin-2 role, 241–242
- Insulin-like growth factor-II (IGF-II), 384
- Integrins, *see also* Extracellular matrix
 $\alpha v \beta 3$
 angiogenesis pathway, 321–322
 expression on angiogenic blood vessels, 321
 $\alpha v \beta 5$, angiogenesis pathway, 321–322
 antagonists
 cilengitide, 326–327
 development, 326–327
 endogenous inhibitors and angiogenesis
 inhibition, 324
 $\beta 3$ knockout and knock-in studies, 322
 cancer role of αv integrins
 $\alpha v \beta 5$ in invasion and metastasis, 326
 $\beta 3$ integrin promotion of
 anchorage-independent growth and
 metastasis, 325–326
 RGD-targeted nanoparticle applications, 326
 signaling effects on tumor-associated
 cells, 325
 tumor expression, 324–325
 growth factor binding, 323
 internalization and recycling, 323–324
 neurovascular patterning, 322–323
 polymorphisms, 423
 RGD-binding integrins, 319–320
 vascular endothelial growth factor receptor signaling
 modulation, 186–187
- Interleukin-8 (IL-8), polymorphisms, 423
- Intersegmental vessel (ISV), formation in
 zebrafish, 143
- Intrauterine growth restriction (IUGR), 388
- Intussusceptive angiogenesis, 278–279
- Ischemic retinopathy, *see* Ocular neovascularization
- ISV, *see* Intersegmental vessel
- IUGR, *see* Intrauterine growth restriction
- J**
- Jagged1, 45, 50
- JNK, *see* Jun amino-terminal kinase
- Jun amino-terminal kinase (JNK), 252
- K**
- Kaposi's sarcoma herpes virus (KSHV), lymphatic
 reprogramming of vascular endothelial
 cells, 127
- KDR, *see* VEGFR-2
- KRIT1, 439–440, 453
- KSHV, *see* Kaposi's sarcoma herpes virus
- L**
- LAM, *see* Lymphangioliomyomatosis
- Leukocyte trafficking, 3
- Lexatumumab, 255–256
- Linifinib, 470
- LM, *see* Lymphatic malformation
- Long-term potentiation (LTP), VEGF-A role, 169
- LTP, *see* Long-term potentiation
- Lumen, *see* Tubulogenesis
- Lung cancer, antiangiogenesis therapy for
 non-small-cell lung cancer, 475,
 479–480
- Lymphangiogenesis
 hematopoietic cells in development, 99–100
 history of study, 117
 initial steps, 117–120
 leukocyte-mediated remodeling and
 lymphatic endothelium expansion,
 100–104
 lymphatic endothelial cell
 blood vessel endothelial cell comparison,
 114–116
 overview, 100, 102, 107
 plasticity of cell fate, 122–123
 lymphatic system structure and function,
 113–116
 maturation and postdevelopmental remodeling role,
 123–124
 myeloid–endothelial plasticity in inflammation and
 cancer, 106–109
 phylogenetic standpoint, 117
 Prox1 role, 120–121
 separation of blood and lymphatic vesicles,
 121–122
 tumors and lymph node metastasis, 104–107
 vascular normalization, 348
 zebrafish
 development, 150–152
 lymphatic endothelial cell origins, 150
- Lymphangioliomyomatosis (LAM), 126–129
- Lymphatic malformation (LM), gene mutations,
 456–457
- Lymphatic vessel endothelial hyaluronan receptor-1
 (LYVE-1), lymphangiogenesis role, 107,
 109, 119, 151
- Lymphedema
 gene mutations
 hypotrichosis–lymphedema–telangiectasia
 syndrome, 458–459
 late-onset lymphedema, 458
 primary congenital lymphedema,
 457–458

- primary disease types, 124–125
 - secondary disease, 125–126
 - treatment, 126
- LYVE-1, *see* Lymphatic vessel endothelial hyaluronan receptor-1
- M**
- Macrophage
- stromal angiogenesis regulation in tumor microenvironment, 405–406
 - tumor-associated macrophage, 104, 405
- Mammalian target of rapamycin (mTOR), inhibition for cancer treatment, 481
- Mast cell, stromal angiogenesis regulation in tumor microenvironment, 406
- Matrix metalloproteinases (MMPs)
- carcinoma-associated fibroblasts, 399
 - polymorphisms, 423–424
 - propranolol downregulation, 301
 - stromal angiogenesis regulation in tumor microenvironment, 404
- MEK1, 322
- Mesenchymal stem cell (MSC), stromal angiogenesis regulation in tumor microenvironment, 405
- Metastasis
- antiangiogenesis therapy, 483
 - integrins
 - $\alpha\beta 5$ integrin role, 326
 - $\beta 3$ integrin promotion, 325–326
 - lymphangiogenesis and lymph node metastasis, 104–107
- MGMT, 327
- MicroRNA (miRNA)
- angiogenesis modulation by specific RNAs, 87–91
 - Dicer role in endothelial cell function and angiogenesis, 86–87
 - endothelial cell synthesis regulation, 91–93
 - functional overview, 85–86
 - history of study, 284
 - therapeutic applications, 93–94
 - tumor endothelial cell, 282–283
- miRNA, *see* MicroRNA
- MMPs, *see* Matrix metalloproteinases
- Mother vessel (MV), 205–206
- MSC, *see* Mesenchymal stem cell
- mTOR, *see* Mammalian target of rapamycin
- Mts1, 399
- MV, *see* Mother vessel
- Myocardial infarction, placental growth factor levels, 218–219
- N**
- Neovascular glaucoma, *see* Ocular neovascularization
- Neural stem cell (NSC)
- neurovascular niche for neurogenesis, 165–167
 - vascular endothelial growth factor signaling, 167–168
- Neuropilin-1, 265
- Neurovascular interactions
- central nervous system
 - axon outgrowth and neuronal migration
 - guidance by blood vessels, 164–165
 - regulators of angiogenesis in development and disease, 183–184
 - vessel development and maturation, 161–162
 - integrins in patterning, 322–323
 - niche for neurogenesis, 165–167
 - overview, 159–161
 - prospects for study, 169–170
 - vascular endothelial growth factor
 - guidance cue for growing axons, 168–169
 - neural plasticity control by VEGF-A, 169
 - neuronal progenitor signaling, 167–168
- Neutrophil, stromal angiogenesis regulation in tumor microenvironment, 406–407
- NF- κ B, *see* Nuclear factor- κ B
- Nitric oxide (NO), thrombospondin and signaling suppression, 253–255
- Nitric oxide synthase (NOS), polymorphisms in endothelial enzyme, 422–423
- NO, *see* Nitric oxide
- Non-small-cell lung cancer, *see* Lung cancer
- Norrie disease, 163–164
- NOS, *see* Nitric oxide synthase
- Notch
- signaling, 45–46, 62
 - structure, 61
 - therapeutic targeting, 69
 - tip/stalk cell selection, 47–51, 62–63
 - tumor angiogenesis signaling, 67–69
 - types and ligands, 45–46, 61–62
 - vascular endothelial growth factor signaling
 - cross-talk, 51–52
- NRP, vascular endothelial growth factor receptor complexes, 185–186
- NSC, *see* Neural stem cell
- Nuclear factor- κ B (NF- κ B), corticosteroid suppression, 299
- O**
- Obesity, placental growth factor blockade therapy, 222
- Ocular neovascularization
- angiogenesis inhibition therapy
 - age-related macular degeneration, 359–362
 - diabetic macular edema, 367–370
 - neovascular glaucoma, 365–367
 - overview, 359
 - proliferative diabetic retinopathy, 363–365
 - retinal vein occlusion, 370–371

Index

- Ocular neovascularization (*Continued*)
 angiogenic factors, 358–359
 overview of diseases, 357–358
 placental growth factor blockade therapy,
 220–221
- OEC, *see* Outgrowth endothelial cell
- OIR, *see* Oxygen-induced ischemic retinopathy
- Osler–Rendu–Weber syndrome, *see* Hereditary
 hemorrhagic telangiectasia
- OSM, 440
- Outgrowth endothelial cell (OEC), 23
- Ovarian cancer, antiangiogenesis therapy, 483
- Oxygen-induced ischemic retinopathy (OIR), 50
- P**
- Pancreatic cancer, antiangiogenesis therapy, 483
- PAR-1, *see* Proteinase-activated receptor-1
- Paxopanib, 470, 480
- PDCD10, 440
- PDGF, *see* Platelet-derived growth factor
- PDPN, *see* Podoplanin
- PDT, *see* Photodynamic therapy
- PECAM, 309–310, 312
- PEDE, *see* Pigment-epithelium-derived factor
- Pegaptanib, age-related macular degeneration
 management, 361
- Perivascular cell (PVC), vascular normalization
 targeting, 342
- Permeability, *see* Vascular permeability
- Peroxisome proliferator-activated receptor (PPAR),
 stromal angiogenesis regulation in tumor
 microenvironment, 403
- PHD2, 314, 341–342
- Phosphoinositide 3-kinase (PI3K), vascular endothelial
 growth factor receptor signaling, 179,
 183–185
- Phospholipase C (PLC), vascular endothelial
 growth factor receptor signaling,
 181–182
- Photodynamic therapy (PDT), age-related macular
 degeneration, 361
- PI3K, *see* Phosphoinositide 3-kinase
- Pigment-epithelium-derived factor (PEDF),
 165–166, 365
- PKC, *see* Protein kinase C
- Placenta, *see* Preeclampsia
- Placental growth factor (PlGF)
 bone fracture repair role, 220
 cancer role
 hematologic malignancies, 226–227
 pathogenesis, 222–225
 therapeutic targeting, 225–226
 deficiency
 colitis, 220
 limb ischemia, 219
 myocardial infarction, 218–219
 preeclampsia, 220
 sepsis, 220
 disease modification role, 214, 218
 FLT1 signaling, 213–214
 functional overview, 179, 211–212, 214
 gene, 211
 nervous system expression, 219
 pleiotropic activity, 212–213
 receptors, 212
 therapeutic targeting
 atherosclerosis, 221
 cirrhosis, 221
 delayed-type hypersensitivity, 221
 emphysema, 222
 obesity, 222
 ocular neovascularization, 220–221
 rheumatoid arthritis, 221
 transgenic and knockout mouse phenotypes,
 215–218
 vascular normalization targeting, 341
 wound healing and expression, 219–220
- Platelet-derived growth factor (PDGF)
 PDGF- β signaling in central nervous
 system, 162
 placenta, 384
 proliferative diabetic retinopathy role, 364
 stromal angiogenesis regulation in tumor
 microenvironment, 402–403
- PLC, *see* Phospholipase C
- Plexins, 265–266
- PlGF, *see* Placental growth factor
- Podoplanin (PDPN), lymphangiogenesis role,
 119, 122
- PPAR, *see* Peroxisome proliferator-activated receptor
- Preeclampsia
 angiogenesis and remote history, 387–388
 clinical features, 384–385
 intrauterine growth restriction, 388
 placenta development
 angiogenesis, 378–380
 angiogenic factors as regulators, 382–384
 overview, 377–378
 pseudovasculogenesis, 379, 381–382
 vasculogenesis, 378
 placental growth factor levels, 220, 382, 386
 soluble Flt-1 expression, 386–387
 spiral artery remodeling, 385
- Proliferative diabetic retinopathy, *see* Ocular
 neovascularization
- Propranolol, *see* Infantile hemangioma
- Prostate cancer, antiangiogenesis therapy, 483
- Proteinase-activated receptor-1 (PAR-1),
 polymorphisms, 424
- Protein C, 3–4
- Protein kinase B, *see* Akt

- Protein kinase C (PKC)
 ocular neovascularization role, 358
 tubulogenesis role, 79
 vascular endothelial growth factor receptor
 signaling, 181–182
- Protein S, 3–4
- Prox1, lymphangiogenesis role, 120–121
- Psoriasis, vascular normalization studies, 346–347
- PTEN, 89
- PVC, *see* Perivascular cell
- Q**
- QTL, *see* Quantitative trait loci
- Quantitative trait loci (QTL), angiogenesis response
 in animals, 425–427
- R**
- Raf-1, 322
- Rag, 99
- Ranibizumab
 age-related macular degeneration management,
 361–362
 diabetic macular edema management, 368–370
 retinal vein occlusion management, 371
- Rap1a, 439
- Rap1b, 313
- Rasa1, 437, 439, 452
- RCC, *see* Renal cell carcinoma
- Renal cell carcinoma (RCC), antiangiogenesis therapy,
 476, 480–481
- Resistance, antiangiogenic drugs
 extrinsic resistance, 502–503
 intrinsic resistance, 503
- Retina, *see also* Ocular neovascularization
 vascular endothelial growth factor patterning,
 36–37
 zebrafish development, 149
- Retinal vein occlusion, *see* Ocular neovascularization
- Retinopathy, *see* Ocular neovascularization
- Rheumatoid arthritis, placental growth factor blockade
 therapy, 221
- Rho-associated protein kinase (ROCK), 80
- ROCK, *see* Rho-associated protein kinase
- RU-486
- Ruboxistaurin, diabetic macular edema
 management, 370
- S**
- SDF-1, 166
- Semaphorins
 history of study, 263–264
 neurovascular patterning, 323
 receptors, 265–266
 structure, 264–265
 tumor angiogenesis
 inhibition
 Sema3A, 268
 Sema3B, 268–269
 Sema3E, 269–270
 Sema3F, 269
 Sema4A, 270–271
 Sema6A, 271
 promotion
 Sema4D, 267
 Sema5A, 268
 Sema5B, 268
 Sema6D, 267–268
 tumor progression role, 266–267
 types, 264–265
- Sepsis, placental growth factor levels, 220
- ShcA, 450
- Shh, *see* Sonic hedgehog
- Single nucleotide polymorphisms (SNPs), identification
 in angiogenesis regulation, 415–416
- SMADs, 455
- SMC, *see* Smooth muscle cell
- Smooth muscle cell (SMC), vascular properties,
 277–278
- SNPs, *see* Single nucleotide polymorphisms
- Sonic hedgehog (Shh), artery–vein specification in
 zebrafish, 142
- Sorafenib, 469, 480
- Sphingosine kinase (SPK), vascular endothelial growth
 factor receptor signaling, 181
- Sphingosine 1-phosphate, stromal angiogenesis
 regulation in tumor microenvironment,
 404
- SPK, *see* Sphingosine kinase
- Stalk cell
 overview, 41–43
 tip/stalk cell selection
 dynamics, 54–55
 model, 52–54, 62–63
 Notch role, 47–51, 62–63
 prospects for study, 55
 vascular endothelial growth factor role, 47–51
 zebrafish, 143–145
- STATs, 92, 441, 450
- Stroma
 formation and vascular permeability, 207–208
 tumor microenvironment
 fibroblast
 carcinoma-associated fibroblast, 397–400
 functional overview, 396–397
 overview, 395–396
 prospects for study, 407–408
 stromal angiogenesis regulation
 estrogen, 403
 fibroblast growth factor-2, 400–401

Index

- Stroma (*Continued*)
 macrophage, 405–406
 mast cell, 406
 matrix metalloproteinases, 404
 mesenchymal stem cell, 405
 neutrophil, 406–407
 peroxisome proliferator-activated
 receptor, 403
 platelet-derived growth factor, 402–403
 sphingosine 1-phosphate, 404
 thrombospondin-1, 401
 transforming growth factor- β , 401–402
 vascular endothelial growth factor, 400
- Sunitinib, 469, 480
- T**
- TAM, *see* Tumor-associated macrophage
- T cell-specific adapter molecule (TSAd), vascular
 endothelial growth factor receptor
 signaling, 180, 182
- TEC, *see* Tumor endothelial cell
- TEK, 440–441, 450
- TGF- β , *see* Transforming growth factor- β
- Thrombospondin (TSP)
 angiogenesis modulation, 250
 CD36 receptor
 apoptosis induction, 252–253
 interactions with VEGFR2, 251–252
 endothelial cell migration and proliferation
 inhibition, 253
 history of study, 249
 nitric oxide signaling suppression, 253–255
 prospects for study, 257
 stromal angiogenesis regulation in tumor
 microenvironment by TSP-1, 401
 therapy with exogenous thrombospondins
 delivery, 256–257
 efficacy enhancement strategies, 256
 overview, 255
 types, 255–256
 vascular endothelial growth factor antagonism, 250–
 252
- Tie, *see* Angiopoietin–Tie signaling
- Tight junction, 306–310
- Tip cell
 overview, 41–43
 tip/stalk cell selection
 dynamics, 54–55
 model, 52–54, 62–63
 Notch role, 47–51, 62–63
 prospects for study, 55
 vascular endothelial growth factor role, 47–51
 zebrafish, 143–145
- TRAIL, *see* Tumor necrosis factor-related
 apoptosis-inducing ligand
- Transforming growth factor- β (TGF- β)
 integrin activation, 167
 stromal angiogenesis regulation in tumor
 microenvironment, 401–402
- Triamcinolone, retinal vein occlusion management, 371
- TSAd, *see* T-cell-specific adapter molecule
- TSC genes, 126
- TSP, *see* Thrombospondin
- Tubulogenesis
 cell hollowing model, 63–64
 chloride channels, 65
 cord hollowing model, 64
 endothelial cell
 cell–cell junctions, 78
 polarity, 65–66, 78–79
 extracellular matrix modulation, 66–67
 morphological changes
 junctional remodeling, 80–81
 lumen expansion, 81
 selective sprouting model, 65
 VEGFR-2 signaling, 79–80
 vesicular trafficking, 64–65
 zebrafish, 145–147
- Tumor angiogenesis
 angiopoietin-2 role, 242–244
 Notch signaling, 67–69
 semaphorin modulation
 inhibition
 Sema3A, 268
 Sema3B, 268–269
 Sema3E, 269–270
 Sema3F, 269
 Sema4A, 270–271
 Sema6A, 271
 promotion
 Sema4D, 267
 Sema5A, 268
 Sema5B, 268
 Sema6D, 267–268
 vascular mimicry, 81
- Tumor-associated macrophage (TAM), 104, 405
- Tumor endothelial cell (TEC)
 abnormalities of tumor vasculature
 abnormal sprouts, 280
 endothelial monolayer, 280
 intercellular openings, 280
 morphology, 279
 tumor progression role, 285–286
 vascular endothelial growth factor levels,
 280–281
 antiangiogenic versus antiendothelial therapy,
 287–289
- culture
 human tumor cells, 283
 mouse tumor models, 283, 285
 overview, 281

- endothelium
 - heterogeneity
 - mechanisms, 7–10
 - scope, 6–7
 - therapeutic targeting, 10–11
 - gene expression, 282
 - isolation, 281–283
 - microRNA, 282–283
 - origins of tumor epithelium, 286–287
 - prospects for study, 289
- Tumor microenvironment, *see* Stroma
- Tumor necrosis factor–related apoptosis-inducing ligand (TRAIL), 252
- Tumstatin, 324

- V**
- Vandetamib, 470, 480
- Vascular endothelial growth factor (VEGF)
 - cellular sources, 497
 - endothelial cell response in developing vessels, 30–33
 - inhibitor therapy, *see also specific diseases and drugs*
 - assessment, 502
 - biomarkers, 485–487
 - clinical trial overview, 497–501
 - drug types, 469–470
 - prospects for study, 487
 - resistance
 - extrinsic, 502–503
 - intrinsic, 503
 - toxicity, 483–485, 501–502
 - intersegmental vessel formation in zebrafish, 143
 - isoforms, 43, 177, 497
 - leukocyte-mediated remodeling and lymphatic endothelium expansion, 101–104
 - nascent blood vessel patterning, 33–35
 - neurovascular interactions
 - guidance cue for growing axons, 168–169
 - neural plasticity control by VEGF-A, 169
 - neuronal progenitor signaling, 167–168
 - polymorphisms, 417–421
 - splice variants, 496
 - tip/stalk cell selection, 47–51
 - tissue-level patterning, 36–37
- VEGF-A
 - corticosteroid downregulation, 298
 - general effects on vessels, 30
 - inducers, 43
 - knockout mice, 44–45
 - propranolol downregulation, 300
- VEGF-C targeting for lymphedema, 126
- Vascular endothelial growth factor receptor (VEGFR), *see also* VEGFR-1; VEGFR-2; VEGFR-3
 - integrin binding, 323
 - lymphangiogenesis role, 117–118
 - Notch signaling cross-talk, 51–52
 - ocular neovascularization role
 - age-related macular degeneration, 360
 - diabetic macular edema, 367
 - overview, 358–359
 - proliferative diabetic retinopathy, 363
 - preeclampsia levels, 386–387
 - signaling
 - endosome internalization and signaling, 187
 - heterodimers, 185
 - integrin modulation, 186–187
 - NRP complex, 185–186
 - overview, 43–45, 175–176
 - permeability, 183
 - prospects for study, 187–188
 - survival signaling, 182–183
 - VEGFR-1, 176–180
 - VEGFR-2, 180–183
 - VEGFR-3, 183–185
 - stromal angiogenesis regulation in tumor microenvironment, 400
 - thrombospondin antagonism, 250–252
 - tumor levels, 280–281
 - VEGF-A receptors, 30, 43
- Vascular normalization
 - age-related macular degeneration studies, 346
 - atherosclerosis studies, 347–348
 - benign tumor studies, 344–346
 - cancer treatment
 - clinical studies, 343–344
 - preclinical studies
 - actual and potential therapeutic benefits, 336–337
 - angiopoietin–Tie2 blockade, 340
 - indirect inhibitors of angiogenesis, 342–343
 - number of studies, 338
 - perivascular cell targets, 342
 - PHD2, 231–342
 - placental growth factor, 341
 - vascular endothelial growth factor blockade, 338–340
 - hereditary hemorrhagic telangiectasia studies, 347
 - hypothesis, 335–336
 - lymphatic vasculature, 348
 - overview, 333–334
 - prospects for study, 348–349
 - psoriasis studies, 346–347
 - tumor vascular abnormalities, 334–335
- Vascular permeability
 - acute vascular permeability, 201–204
 - assays, 199
 - basal vascular permeability, 200–201
 - chronic vascular permeability, 204–206
 - definition, 197–199
 - stroma formation, 207–208
 - VEGFR-2 modulation, 184

Index

- Vasculogenesis
 features versus angiogenesis, 278
 placenta, 378
- VE-cadherin, 78–79, 99, 309–311, 313
- VEGF, *see* Vascular endothelial growth factor
- VEGFR, *see* Vascular endothelial growth factor
- VEGFR-1 (Flt-1), *see also* Vascular endothelial growth factor receptor
 knockout effects, 30
 placental growth factor binding and signaling, 213–214
 preeclampsia and soluble Flt-1 expression, 386–387
 signaling, 43–44, 176–180
 soluble form, 32–33
 splice variants, 32
- VEGFR-2 (Flk-1/KDR), *see also* Vascular endothelial growth factor receptor
 CD36 interactions, 251–252
 endothelial progenitor cell marker, 20–22
 integrin binding, 323
 polymorphisms, 421
 signaling, 180–183
 tubulogenesis signaling, 79–80
- VEGFR-3
 lymphangiogenesis role, 117–118
 lymphedema mutations, 457
- Venous malformation
 cutaneomucosal venous malformation, 440–441
 gene mutations, 450–452
- VE-PTP, 238, 309, 311–312
- Vesiculo–vacuolar organelle (VVO), 201–204
- VMCM, *see* Cutaneomucosal venous malformation
- VVO, *see* Vesiculo–vacuolar organelle
- ## W
- Wnt, central nervous system signaling, 163
- Wound healing, placental growth factor expression, 219–220
- ## Y
- Yolk sac, vascular endothelial growth factor patterning, 37
- ## Z
- Zebrafish angiogenesis
 advantages as model system, 137–138
 axial vessels
 angioblast midline migration, 140
 artery–vein specification, 140–143
 cranial vasculature
 endothelial junctions in vascular permeability, 148–149
 lateral dorsal aortae and cranial vasculature, 147–148
 endothelial precursor cell origin and specification, 138–140
 intersegmental vessel formation, 143
 lymphangiogenesis
 development, 150–152
 lymphatic endothelial cell origins, 150
 retinal vasculature, 149
 tip/stalk cell specification, 143–145
 tubulogenesis, 145–147